Corporate Profile

History

January 2013	Is launched with capital of 1,000,000 yen as a wholly owned subsidiary of RaQualia Inc. Acquires the following compounds as intellectual property: ・EP4 antagonist / AAT-007, AAT-008 ・5-HT4 partial agonist / AAT-009 ・COX-2 inhibitor / AAT-076 President Shinichi Koizumi
June 2013	Acquires management rights from RaQualia Inc.
September 2014	Relocation of head office to Showa-ku, Nagoya
March 2015	Akihiro Furuta becomes president Becomes fully independent of RaQualia
June 2015	Issues new shares to third parties (capital 9,750,000 yen)
August 2015	Issues new shares to third parties (capital 17,000,000 yen)
November 2015	Acquires CB2 agonist intellectual property from RaQualia Inc. Issues new shares to third parties (capital 32,000,000 yen)
January 2016	Concludes license agreement with RMX for AAT-076 and AAT-007 in China. Issues new shares to third parties (capital 37,000,000 yen)
March 2016	Issues new shares to third parties (capital 62,000,000 yen)
December 2016	Concludes license agreement with Ningbo Tai Kang for AAT-007 in China.
May 2017	Issues new shares to third parties (capital 87,000,000 yen)
December 2017	Concludes worldwide license agreement (excluding China and Taiwan) with Arrys Therapeutics for AAT-007 and AAT-008 Transition to a company with board of directors / company auditor
February 2018	Concludes license agreement with NewBay Medical Technology for AAT-008 in China and Taiwan Concludes worldwide license agreement with Aratana Therapeutics for AAT-008 in animal health
March 2018	Transition to a company with audit and supervisory committee
August 2018	Relocation of head office to Nakamura-ku, Nagoya